Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML

Documenti analoghi

• HAT ‐ PCR is non‐inferior to NGS when quantifying measurable residual disease for myeloma
  di: Elizabeth Hughes, et al.
  Pubblicazione: (2026)
• Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease
  di: Miguel Alcoceba, et al.
  Pubblicazione: (2024)
• STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B‐cell acute lymphoblastic leukaemia
  di: Xiuli Xu, et al.
  Pubblicazione: (2024)
• Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan
  di: Aika Fuseya, et al.
  Pubblicazione: (2026)
• Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights
  di: Boaz Nachmias, et al.
  Pubblicazione: (2025)